Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.

J Neuroinflammation · 2023 · PMC10463946 · PMID 37633912

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

showed a trendp = 0.057so close (0.05 < p ≤ 0.1)

Interestingly, remibrutinib treatment showed a trend for reduction in PMA/ionomycin-induced Th17 CD4 + frequencies (Fig. 3 c, p = 0.057 and p = 0.072 for 3 and 30 mg/kg dose, respectively.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.